Patents Assigned to Amgen
  • Stabilized receptor polypeptides and uses thereof
    Patent number: 11685770
    Abstract: The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: June 27, 2023
    Assignee: Amgen Inc.
    Inventors: Jeonghoon Sun, Lei-Ting Tony Tam, Mark Leo Michaels, Thomas Charles Boone, Rohini Deshpande, Yue-Sheng Li, Huiquan Han
  • BTNL3 PROTEINS, NUCLEIC ACIDS AND ANTIBODIES AND USES THEREOF
    Publication number: 20230192802
    Abstract: The invention provides novel BTNL3 proteins, including multimers, fragments, fusion proteins, and variants. In addition, antibodies that can bind to BTNL3 proteins and nucleic acids encoding BTNL3 proteins are provided. Methods of making BTNL3 proteins using such nucleic acids are also provided. Uses for BTNL3 proteins, and agonists or antagonists thereof, are described.
    Type: Application
    Filed: August 23, 2022
    Publication date: June 22, 2023
    Applicant: Amgen Inc.
    Inventors: Heather ARNETT, Sabine Schadow ESCOBAR, Ryan Michael SWANSON, Joanne Louise VINEY
  • METHODS FOR INCREASING MANNOSE CONTENT OF RECOMBINANT PROTEINS
    Publication number: 20230193340
    Abstract: The present invention relates to methods of modulating the mannose content of recombinant proteins.
    Type: Application
    Filed: February 22, 2023
    Publication date: June 22, 2023
    Applicant: AMGEN INC.
    Inventors: Jian WU, Sean DAVERN, Simina Crina PETROVAN, Michael Charles BRANDENSTEIN, Katherine Rose LINDAHL, Shawn Erik LILLIE
  • PROCESS OF MAKING IVABRADINE HYDROCHLORIDE DRUG PRODUCT
    Publication number: 20230181472
    Abstract: A new process for making ivabradine hydrochloride drug product reduces the amount of amorphous ivabradine hydrochloride in the drug product.
    Type: Application
    Filed: October 29, 2019
    Publication date: June 15, 2023
    Applicant: AMGEN INC.
    Inventors: Neil Obrad MACPHAIL, Angela Marie OLSOFSKY, Tiffany Lee THIEL, Yong XIE
  • ACTIVATABLE POLYPEPTIDE COMPLEX
    Publication number: 20230183382
    Abstract: The present disclosure relates to activatable anti-EGFR, anti-CD3, heteromultimeric bispecific polypeptide complexes (HBPCs) and methods of making and using the same.
    Type: Application
    Filed: October 14, 2022
    Publication date: June 15, 2023
    Applicants: CytomX Therapeutics, Inc., Amgen, Inc.
    Inventors: Leila M. BOUSTANY, Madan M. PAIDHUNGAT, Ellaine Anne Mariano FOX, Sayantan MITRA, W. Michael KAVANAUGH, Raffaella BRIANTE, Jennitte LeAnn STEVENS
  • Synthesis of Vinyl Cyclobutyl Intermediates
    Publication number: 20230183164
    Abstract: Provided herein are processes for synthesizing intermediates useful in preparing Mcl-1 inhibitors. In particular, provided herein are processes for synthesizing compound F, or a salt thereof, wherein R1 and OPG2 are described herein. Compound F can be useful in synthesizing compound A1, or a salt of solvate thereof, and compound A2, or a salt of solvate thereof.
    Type: Application
    Filed: May 4, 2021
    Publication date: June 15, 2023
    Applicant: AMGEN INC.
    Inventors: Austin G. SMITH, Michael T. CORBETT, Neil Fred LANGILLE, Kyle D. BAUCOM, Peter K. DORNAN, Gabrielle ST- PIERRE, Philipp C. ROOSEN, Sheng CUI, Roberto PROFETA
  • Mammalian cell culture
    Patent number: 11673941
    Abstract: The invention provides a method for culturing mammalian cells. The method provides greater control over cell growth to achieve high product titer cell cultures.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: June 13, 2023
    Assignee: AMGEN INC.
    Inventors: Brian D. Follstad, Rebecca E. McCoy, Arvia E. Morris
  • Rotationally biased insertion mechanism for a drug delivery pump
    Patent number: 11672905
    Abstract: An insertion mechanism for a drug pump includes an insertion mechanism housing; a sleeve; a rotational biasing member initially held in an energized state; a retraction biasing member and a hub connected to a proximal end of a needle, wherein the retraction biasing member is held initially in an energized state between the hub and the sleeve. The needle is inserted into a target tissue by the rotational biasing member and interaction between the hub and housing. Retraction of the needle is caused by decompressing or de-energizing of the retraction biasing member. A drug delivery pump includes an activation mechanism, a drive mechanism, a sterile access connection, and the insertion mechanism. Assembly and operation methods are provided.
    Type: Grant
    Filed: November 18, 2020
    Date of Patent: June 13, 2023
    Assignee: AMGEN INC.
    Inventors: Mark A. Destefano, Lawton Laurence, John C. Love, Ian B. Hanson, Paul F. Bente, IV
  • Gas permeable sealing member for drug container and methods of assembly
    Patent number: 11672733
    Abstract: Drug delivery devices, sealing members for containers housed within such drug delivery devices, and related methods of assembly are disclosed. The drug delivery device may include a housing, a container disposed in the housing and having an interior volume, a drug disposed in the interior volume, and a septum. The container may have an opening formed in an end surface and which communicates with the interior volume. The septum may include a proximal end inserted through the opening into the interior volume of the container. Additionally, the septum may include a distal end having a flange disposed outwardly of the proximal end and contacting the end surface of the container. At least an end portion of the flange may be made of a material that is permeable to a gaseous sterilizing agent.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: June 13, 2023
    Assignee: AMGEN INC.
    Inventors: Cheng-Chieh Chou, Mingda Eu, Ren-Yo Forng, Wael Mismar
  • Synthesis of Vinylic Protected Alcohol Intermediates
    Publication number: 20230174496
    Abstract: Provided herein are processes for synthesizing intermediates useful in preparing Mcl-1 inhibitors. In particular, provided herein are processes for synthesizing compound D, wherein OPG and R1 are described herein. Compound D can be useful in synthesizing compound A1, or a salt of solvate thereof, and compound A2, or a salt of solvate thereof.
    Type: Application
    Filed: April 27, 2021
    Publication date: June 8, 2023
    Applicant: AMGEN INC.
    Inventors: Austin G. SMITH, Liang HUANG
  • ACTIVATABLE POLYPEPTIDE COMPLEX
    Publication number: 20230174995
    Abstract: The present disclosure relates to activatable heteromultimeric bispecific polypeptide complexes (HBPCs) and methods of making and using the same.
    Type: Application
    Filed: October 14, 2022
    Publication date: June 8, 2023
    Applicants: CytomX Therapeutics, Inc., Amgen, Inc.
    Inventors: Leila M. BOUSTANY, Madan M. PAIDHUNGAT, Ellaine Anne Mariano FOX, Sayantan MITRA, W. Michael KAVANAUGH, Raffaella BRIANTE, Jennitte LeAnn STEVENS
  • PHARMACEUTICAL FORMULATION
    Publication number: 20230167176
    Abstract: Described herein are stable high concentration bispecific antibody construct formulations, wherein the formulations have less than 2% high molecular weight species of the bispecific antibody construct in the formulation under storage conditions at various time points.
    Type: Application
    Filed: April 28, 2021
    Publication date: June 1, 2023
    Applicant: AMGEN INC.
    Inventors: Twinkle R. Christian, Bharadwaj Jagannathan
  • Ring Closing Synthesis of Macrocyclic MCL-1 Inhibitor Intermediates
    Publication number: 20230167130
    Abstract: Provided herein are processes for synthesizing Mcl-1 inhibitors and intermediates such as compound F that can be used to prepare them where the variable PG is as defined herein. In particular, provided herein are processes for synthesizing compound A1, and salts or solvates thereof and compound A2, and salts and solvates thereof.
    Type: Application
    Filed: May 5, 2021
    Publication date: June 1, 2023
    Applicant: AMGEN INC.
    Inventors: Austin G. SMITH, Jason S. TEDROW, Gabrielle ST-PIERRE, Oliver Ralf THIEL, Liang HUANG, Philipp C. ROOSEN, John T. COLYER, Kyle D. BAUCOM, Ari ERICSON, Matthew G. BEAVER, Rahul P. SANGODKAR, Michael A. LOVETTE, Robert Ronald MILBURN, Alan H. CHERNEY, Sheng CUI
  • Drug delivery systems and methods with back pressure sensing
    Patent number: 11660391
    Abstract: Systems and methods for injecting a drug and detecting tissue induced back pressure are disclosed. A drug delivery system may include a reservoir filled or fillable with a drug, an administration member connected or connectable in fluid communication with the reservoir, a drive assembly, and a pressure sensor. The administration member may be configured for insertion into and subsequently retraction from a patient. The drive assembly may be configured to urge the drug from the reservoir to deliver a dose of the drug to the patient via the administration member. The pressure sensor may be configured to detect tissue back pressure during use of the drug delivery system, including after dose completion and prior to retraction of the administration member. The drug delivery system may be controlled in a manner that accounts for the tissue back pressure measurement.
    Type: Grant
    Filed: January 17, 2020
    Date of Patent: May 30, 2023
    Assignee: AMGEN INC.
    Inventors: Daniel Eduardo Groszmann, Scott Robert Gibson
  • Light-activated ultrasonic delivery and manipulation of liquid medication from a drug reservoir
    Patent number: 11660435
    Abstract: The devices, assemblies, and methods described herein utilize photoacoustic principals to create a jet of fluid using a ultrasonic resonance member and a pulsed laser light beam. The ultrasonic resonance member is a treated substrate having an liquid interface surface in contact with a fluid. When a pulsed laser light beam is applied to the treated substrate, pressure is generated via induced ultrasonic waves to urge the fluid into a jet stream.
    Type: Grant
    Filed: October 5, 2020
    Date of Patent: May 30, 2023
    Assignee: AMGEN INC.
    Inventors: Mehran Mojarrad, Scott R. Gibson, Heejin Lee
  • Optimized cross-species specific bispecific single chain antibody contructs
    Patent number: 11661462
    Abstract: The present invention provides to a bispecific single chain antibody construct binding to a target cell surface antigen via a first binding domain and to the T cell surface antigen CD3 via a second binding domain, wherein serum albumin is fused to the C-terminus of the antibody construct. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: May 30, 2023
    Assignee: AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Benno Rattel, Matthias Friedrich, Peter Kufer, Patrick Hoffmann, Tobias Raum, Markus Münz, Ines Herrmann, Ralf Lutterbüse, Elisabeth Nahrwold
  • PROCESS FOR MANIPULATING THE LEVEL OF GLYCAN CONTENT OF A GLYCOPROTEIN
    Publication number: 20230159974
    Abstract: The present invention provides a method for manipulating the fucosylated glycan content on a recombinant protein.
    Type: Application
    Filed: January 18, 2023
    Publication date: May 25, 2023
    Applicant: AMGEN INC.
    Inventors: Daniel R. LEISKE, Michael T. TRENTALANGE
  • NOVEL PRMT5 INHIBITORS
    Publication number: 20230159510
    Abstract: Described herein are compounds of Formula I and pharmaceutically acceptable salt thereof, stereoisomers, tautomers as well as pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and may have use in treating proliferative, metabolic and blood disorders.
    Type: Application
    Filed: February 11, 2021
    Publication date: May 25, 2023
    Applicant: AMGEN INC.
    Inventors: Jennifer Rebecca ALLEN, Albert AMEGADZIE, Diane Jennifer BEYLKIN, Shon BOOKER, Matthew Paul BOURBEAU, John R. BUTLER, Michael J. FROHN, Sanne Ormholt Schroder GLAD, Birgitte Weinreich HUSEMOEN, Matthew R. KALLER, Todd J. KOHN, Brian Alan LANMAN, Kexue LI, Qingyian LIU, Patricia LOPEZ, Vu Van MA, Francesco MANONI, Jose MEDINA, Ana Elena MINATTI, Jorge PEIRO CADAHIA, Liping PETTUS, Alexander J. PICKRELL, Ian SARVARY, Nuria A. TAMAYO, Mikkel VESTERGAARD
  • Methods and compositions for the treatment of celiac disease, non-celiac gluten sensitivity, and refractory celiac disease
    Patent number: 11655294
    Abstract: Methods and pharmaceutical compositions are provided herein for the treatment of inflammatory disorders, in particular celiac disease, refractory celiac disease and non-celiac gluten sensitivity.
    Type: Grant
    Filed: January 14, 2020
    Date of Patent: May 23, 2023
    Assignees: AMGEN INC., CELIMMUNE LLC
    Inventors: Francisco Leon, Wayne H. Tsuji
  • ANTI-TNF ALPHA ANTIBODY FORMULATIONS
    Publication number: 20230151086
    Abstract: Stable adalimumab formulations are disclosed.
    Type: Application
    Filed: August 19, 2022
    Publication date: May 18, 2023
    Applicant: Amgen Inc.
    Inventors: William J. CALLAHAN, Rahul Rajan KAUSHIK, Joy BRENNAN